Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes
This article will review recent impact of massively parallel next-generation sequencing (NGS) in our understanding and treatment of cancer. While whole exome sequencing (WES) remains popular and effective as a method of genetically profiling different cancers, advances in sequencing technology has e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-06-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fgene.2015.00215/full |
| _version_ | 1819056845592985600 |
|---|---|
| author | Tony eShen Stefan ePajaro-van de Stadt Nai Chien eYeat Jimmy Cheng-Ho Lin |
| author_facet | Tony eShen Stefan ePajaro-van de Stadt Nai Chien eYeat Jimmy Cheng-Ho Lin |
| author_sort | Tony eShen |
| collection | DOAJ |
| description | This article will review recent impact of massively parallel next-generation sequencing (NGS) in our understanding and treatment of cancer. While whole exome sequencing (WES) remains popular and effective as a method of genetically profiling different cancers, advances in sequencing technology has enabled an increasing number of whole-genome based studies. Clinically, NGS has been used or is being developed for genetic screening, diagnostics, and clinical assessment. Though challenges remain, clinicians are in the early stages of using genetic data to make treatment decisions for cancer patients. As the integration of NGS in the study and treatment of cancer continues to mature, we believe that the field of cancer genomics will need to move towards more complete 100% genome sequencing. Current technologies and methods are largely limited to coding regions of the genome. A number of recent studies have demonstrated that mutations in non-coding regions may have direct tumorigenic effects or lead to genetic instability. Non-coding regions represent an important frontier in cancer genomics. |
| first_indexed | 2024-12-21T13:29:53Z |
| format | Article |
| id | doaj.art-6cd322e7d18a42cfa308ccf4374e7205 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-12-21T13:29:53Z |
| publishDate | 2015-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-6cd322e7d18a42cfa308ccf4374e72052022-12-21T19:02:20ZengFrontiers Media S.A.Frontiers in Genetics1664-80212015-06-01610.3389/fgene.2015.00215140044Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomesTony eShen0Stefan ePajaro-van de Stadt1Nai Chien eYeat2Jimmy Cheng-Ho Lin3Rare Genomics InstituteRare Genomics InstituteRare Genomics InstituteRare Genomics InstituteThis article will review recent impact of massively parallel next-generation sequencing (NGS) in our understanding and treatment of cancer. While whole exome sequencing (WES) remains popular and effective as a method of genetically profiling different cancers, advances in sequencing technology has enabled an increasing number of whole-genome based studies. Clinically, NGS has been used or is being developed for genetic screening, diagnostics, and clinical assessment. Though challenges remain, clinicians are in the early stages of using genetic data to make treatment decisions for cancer patients. As the integration of NGS in the study and treatment of cancer continues to mature, we believe that the field of cancer genomics will need to move towards more complete 100% genome sequencing. Current technologies and methods are largely limited to coding regions of the genome. A number of recent studies have demonstrated that mutations in non-coding regions may have direct tumorigenic effects or lead to genetic instability. Non-coding regions represent an important frontier in cancer genomics.http://journal.frontiersin.org/Journal/10.3389/fgene.2015.00215/fullCancer genomicsexome sequencingnext-generation sequencing (NGS)Non-coding DNAclinical genomics |
| spellingShingle | Tony eShen Stefan ePajaro-van de Stadt Nai Chien eYeat Jimmy Cheng-Ho Lin Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes Frontiers in Genetics Cancer genomics exome sequencing next-generation sequencing (NGS) Non-coding DNA clinical genomics |
| title | Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes |
| title_full | Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes |
| title_fullStr | Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes |
| title_full_unstemmed | Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes |
| title_short | Clinical Applications of Next Generation Sequencing in Cancer: From panels, to exomes, to genomes |
| title_sort | clinical applications of next generation sequencing in cancer from panels to exomes to genomes |
| topic | Cancer genomics exome sequencing next-generation sequencing (NGS) Non-coding DNA clinical genomics |
| url | http://journal.frontiersin.org/Journal/10.3389/fgene.2015.00215/full |
| work_keys_str_mv | AT tonyeshen clinicalapplicationsofnextgenerationsequencingincancerfrompanelstoexomestogenomes AT stefanepajarovandestadt clinicalapplicationsofnextgenerationsequencingincancerfrompanelstoexomestogenomes AT naichieneyeat clinicalapplicationsofnextgenerationsequencingincancerfrompanelstoexomestogenomes AT jimmychengholin clinicalapplicationsofnextgenerationsequencingincancerfrompanelstoexomestogenomes |